Arthur Klausner is currently CEO of Goldilocks Therapeutics, Inc., a start-up company formed to advance nanoparticle technology developed at the Memorial Sloan Kettering Cancer Center for the treatment of acute kidney injury. He currently also serves as boardmember of Monopar Therapeutics, Cennerv Pharmaceutical, and Gem Pharmaceuticals. Prior to his operating roles, Arthur spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures.
Timothy Ehrlich, JD,
Tim Ehrlich is a partner in the Life Sciences practice at Gunderson Dettmer in their Boston office and Synthis' corporate attorney. He also serves as an advisor to the Harvard Law Entrepreneurship Program at Harvard Law School and the Harvard University iLab. Tim is broadly experienced in the life science company formation and entity selection, deal structuring, equity and debt financing transactions, general corporate and governance matters, as well as M&A events and public offerings. Tim received his J.D., cum laude, from Harvard Law School, where he was an editor of the Harvard Journal of Law and Technology. He received an A.B., summa cum laude, from Princeton University.
Muna Abu-Shar, JD, PhD
Muna Abu-Shaar is an intellectual property attorney with over fifteen years of experience in patent counseling for biotechnology and pharmaceutical industry clients ranging from startups to Fortune 500 companies. Muna has a molecular biology technical background with experience in biologics (including antibodies and enzymes), pharmaceutical formulations, vaccines, diagnostics, recombinant technologies, and manufacturing processes. Muna received a J.D. from Fordham Law School, a Ph.D. in Cellular, Molecular & Biophysical Studies from Columbia University, and a B.A. in Natural Sciences from the University of Cambridge.